Bern, July 8 -- Drug manufacturer Novartis has received approval from Swiss authorities for its new Malaria drug named Coartem.
Coartem is the world's first ever Malaria medication suitable for the use on newborn children and infants. The development of the drug is very significant as overwhelming majority of the malaria related deaths are in the under five age group.
Following this development, production and distribution of the drug is expected to start in the next few weeks in Africa. Most of the Malaria related deaths are recorded in the African continent.
Malaria accounted for more than half a million deaths in the world in 2023. Uptill now babies were treated with an experimental dosage of the drug meant for older children, putting...